Terms: = Leukemia AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53 AND Clinical Outcome
114 results:
1. Patient-Specific Measurable Residual Disease Markers Predict outcome in Patients With Myelodysplastic Syndrome and Related Diseases After Hematopoietic Stem-Cell Transplantation.
Tobiasson M; Pandzic T; Illman J; Nilsson L; Weström S; Ejerblad E; Olesen G; Björklund A; Olsnes Kittang A; Werlenius O; Lorentz F; Rasmussen B; Cammenga J; Weber D; Lindholm C; Wiggh J; Dimitriou M; Moen AE; Yip Lundström L; von Bahr L; Baltzer-Sollander K; Jädersten M; Kytölä S; Walldin G; Ljungman P; Groenbaek K; Mielke S; Jacobsen SEW; Ebeling F; Cavelier L; Smidstrup Friis L; Dybedal I; Hellström-Lindberg E
J Clin Oncol; 2024 Apr; 42(12):1378-1390. PubMed ID: 38232336
[TBL] [Abstract] [Full Text] [Related]
2. clinical outcome of Mantle Cell Lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression).
Scheubeck G; Jiang L; Hermine O; Kluin-Nelemans HC; Schmidt C; Unterhalt M; Rosenwald A; Klapper W; Evangelista A; Ladetto M; Jerkeman M; Ferrero S; Dreyling M; Hoster E
Leukemia; 2023 Sep; 37(9):1887-1894. PubMed ID: 37495776
[TBL] [Abstract] [Full Text] [Related]
3. Acute megakaryoblastic leukaemia shows high frequency of chromosome 1q aberrations and dismal outcome.
Pastore F; Gittinger H; Raab S; Tschuri S; Ksienzyk B; Konstandin NP; Schneider S; Rothenberg-Thurley M; Horny HP; Werner M; Sauerland MC; Amler S; Görlich D; Berdel WE; Wörmann B; Braess J; Hiddemann W; Tischer J; Herold T; Metzeler KH; Spiekermann K
Br J Haematol; 2023 Sep; 202(6):1165-1177. PubMed ID: 37455345
[TBL] [Abstract] [Full Text] [Related]
4. LSC17 score complements genetics and measurable residual disease in acute myeloid leukemia: an ALFA study.
Vasseur L; Fenwarth L; Lambert J; de Botton S; Figeac M; Villenet C; Heiblig M; Dumas PY; Récher C; Berthon C; Lemasle E; Lebon D; Lambert J; Terré C; Celli-Lebras K; Dombret H; Preudhomme C; Cheok M; Itzykson R; Duployez N
Blood Adv; 2023 Aug; 7(15):4024-4034. PubMed ID: 37205853
[TBL] [Abstract] [Full Text] [Related]
5. A t(4;13)(q21;q14) translocation in B-cell chronic lymphocytic leukemia causing concomitant homozygous DLEU2/miR15a/miR16-1 and heterozygous ARHGAP24 deletions.
Tolomeo D; Agostini A; Solimando AG; Cunsolo CL; Cimarosto L; Palumbo O; Palumbo P; Carella M; Hernández-Sánchez M; Hernández-Rivas JM; Storlazzi CT
Cancer Genet; 2023 Apr; 272-273():16-22. PubMed ID: 36641997
[TBL] [Abstract] [Full Text] [Related]
6. Clonal evolution in chronic lymphocytic leukemia is associated with an unmutated IGHV status and frequently leads to a combination of loss of tp53 and tp53 mutation.
Bracher S; Fuhrmann I; Jeromin S; Nadarajah N; Kern W; Haferlach T; Haferlach C; Stengel A
Mol Biol Rep; 2022 Dec; 49(12):12247-12252. PubMed ID: 36169893
[TBL] [Abstract] [Full Text] [Related]
7. Somatic mutation-associated risk index based on lncRNA expression for predicting prognosis in acute myeloid leukemia.
Xu Q; Guo T
Hematology; 2022 Dec; 27(1):659-671. PubMed ID: 35666642
[No Abstract] [Full Text] [Related]
8. Primary mediastinal germ cell tumor and clonally related and unique hematologic neoplasms with i(12p) and tp53 mutation: A report of two cases.
Fang H; Toruner GA; Tang Z; Tang G; Weissferdt A; Tashakori M; El Hussein S; Thakral B; Quesada AE; Wang W; Patel KP; Garcia-Manero G; Medeiros LJ; Bueso-Ramos CE; Jelloul FZ
Ann Diagn Pathol; 2022 Aug; 59():151951. PubMed ID: 35489185
[TBL] [Abstract] [Full Text] [Related]
9. Purine nucleoside analogs plus rituximab are an effective treatment choice for hairy cell leukemia-variant.
Wang Y; Wang T; Yu Y; Wang Q; Yan Y; Li R; Sun Q; Xiong W; Lyu R; Yu Z; Liu W; Sui W; Huang W; Wang H; Li C; Wang J; Zou D; An G; Wang J; Qiu L; Yi S
Ann Hematol; 2022 Jun; 101(6):1201-1210. PubMed ID: 35437610
[TBL] [Abstract] [Full Text] [Related]
10. Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma.
Tanaka N; Mori S; Kiyotani K; Ota Y; Gotoh O; Kusumoto S; Nakano N; Suehiro Y; Ito A; Choi I; Ohtsuka E; Hidaka M; Nosaka K; Yoshimitsu M; Imaizumi Y; Iida S; Utsunomiya A; Noda T; Nishikawa H; Ueda R; Ishida T
Haematologica; 2022 Oct; 107(10):2418-2431. PubMed ID: 35417939
[TBL] [Abstract] [Full Text] [Related]
11. clinical outcome of allogeneic stem cell transplantation in patients with B-cell lymphoid malignancies following treatment with targeted small molecule inhibitors.
Mukherjee A; Milton DR; Jabbour EJ; Gulbis AM; Kadia T; Jain N; Ledesma C; Burger J; Ferrajoli A; Wierda W; Medeiros LJ; Kantarjian H; Champlin R; Khouri IF
Leuk Lymphoma; 2022 Apr; 63(4):885-893. PubMed ID: 35225133
[TBL] [Abstract] [Full Text] [Related]
12. Elevated expression of the MYB proto-oncogene like 2 (MYBL2)-encoding gene as a prognostic and predictive biomarker in human cancers.
Xin Z; Li Y; Meng L; Dong L; Ren J; Men J
Math Biosci Eng; 2022 Jan; 19(2):1825-1842. PubMed ID: 35135230
[TBL] [Abstract] [Full Text] [Related]
13. Comparison of myeloid neoplasms with nonclassic 3q26.2/MECOM versus classic inv(3)/t(3;3) rearrangements reveals diverse clinicopathologic features, genetic profiles, and molecular mechanisms of MECOM activation.
Gao J; Gurbuxani S; Zak T; Kocherginsky M; Ji P; Wehbe F; Chen Q; Chen YH; Lu X; Jennings L; Frankfurt O; Altman J; Sukhanova M
Genes Chromosomes Cancer; 2022 Feb; 61(2):71-80. PubMed ID: 34668265
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and Predictive Implications of Cytogenetics and Genomics.
Ljungström V; Baliakas P
Hematol Oncol Clin North Am; 2021 Aug; 35(4):703-713. PubMed ID: 34174981
[TBL] [Abstract] [Full Text] [Related]
15. A higher percentage of leukemic blasts with vacuoles predicts unfavorable outcomes in patients with acute myeloid leukemia.
Song J; Shang B; Pei Y; Shi M; Niu X; Dou L; Drokow EK; Xu F; Bai Y; Sun K
Leuk Res; 2021 Oct; 109():106638. PubMed ID: 34116372
[TBL] [Abstract] [Full Text] [Related]
16. Erythroleukemia: an Update.
Weinberg OK; Arber DA
Curr Oncol Rep; 2021 Apr; 23(6):69. PubMed ID: 33876292
[TBL] [Abstract] [Full Text] [Related]
17. Dissecting the role of tp53 alterations in del(11q) chronic lymphocytic leukemia.
Quijada-Álamo M; Pérez-Carretero C; Hernández-Sánchez M; Rodríguez-Vicente AE; Herrero AB; Hernández-Sánchez JM; Martín-Izquierdo M; Santos-Mínguez S; Del Rey M; González T; Rubio-Martínez A; García de Coca A; Dávila-Valls J; Hernández-Rivas JÁ; Parker H; Strefford JC; Benito R; Ordóñez JL; Hernández-Rivas JM
Clin Transl Med; 2021 Feb; 11(2):e304. PubMed ID: 33634999
[TBL] [Abstract] [Full Text] [Related]
18. Natural small molecule triptonide inhibits lethal acute myeloid leukemia with FLT3-ITD mutation by targeting Hedgehog/FLT3 signaling.
Xu Y; Wang P; Li M; Wu Z; Li X; Shen J; Xu R
Biomed Pharmacother; 2021 Jan; 133():111054. PubMed ID: 33254022
[TBL] [Abstract] [Full Text] [Related]
19. What Is Responsible for Heterogeneity in Mantle Cell Lymphoma Biology and outcomes?
Witzig TE
Hematol Oncol Clin North Am; 2020 Oct; 34(5):825-835. PubMed ID: 32861280
[TBL] [Abstract] [Full Text] [Related]
20. Steroid receptor-associated and regulated protein is a biomarker in predicting the clinical outcome and treatment response in malignancies.
Naderi A
Cancer Rep (Hoboken); 2020 Oct; 3(5):e1267. PubMed ID: 32706923
[TBL] [Abstract] [Full Text] [Related]
[Next]
